Press Release Archives | CereVasc | Neurological Disease Device Company

21 Jan, 2026

CereVasc Completes Enrollment of ETCHES Study of the eShunt® System for the Treatment of Communicating Hydrocephalus

Anthony Sherwood2026-01-29T21:40:11+00:00January 21st, 2026|

30 Jul, 2025

CereVasc, Inc. Announces 100th Patient Treated with the eShunt® System

Anthony Sherwood2026-01-29T21:41:12+00:00July 30th, 2025|

18 Jun, 2025

CereVasc Receives Health Canada Investigational Testing Authorization for STRIDE Clinical Trial of the eShunt® System

Anthony Sherwood2026-01-29T21:42:02+00:00June 18th, 2025|

23 Apr, 2025

CereVasc, Inc. Receives FDA Breakthrough Device Designation for the eShunt® System for Use in Pediatric Patients

cerevasc2025-07-19T20:00:55+00:00April 23rd, 2025|

25 Feb, 2025

CereVasc Announces First Patient Randomized to eShunt® System Treatment in STRIDE Pivotal Trial

Carlos Bonilla2025-07-19T20:00:14+00:00February 25th, 2025|

13 Feb, 2025

CereVasc Receives Approval for STRIDE Clinical Trial of the eShunt® System for the Treatment of Elderly Patients with Normal Pressure Hydrocephalus in Argentina

Carlos Bonilla2025-07-19T20:08:17+00:00February 13th, 2025|

05 Feb, 2025

CereVasc, Inc. Announces Results of Groundbreaking Clinical Study of the eShunt® System in the Treatment of Elderly Patients with Normal Pressure Hydrocephalus

Carlos Bonilla2025-07-19T20:10:54+00:00February 5th, 2025|

14 Jan, 2025

CereVasc Announces First Enrollment in STRIDE Clinical Trial of the eShunt® System for Normal Pressure Hydrocephalus

Carlos Bonilla2025-07-19T19:59:04+00:00January 14th, 2025|

25 Nov, 2024

CereVasc to Present at the Piper Sandler 36th Annual Healthcare Conference

Carlos Bonilla2025-05-20T21:01:09+00:00November 25th, 2024|

25 Sep, 2024

CereVasc Announces Journal of Molecular Therapy Publication Highlighting the eShunt® Platform as a CNS Gene Therapy Delivery Method

Carlos Bonilla2026-01-28T18:14:55+00:00September 25th, 2024|